Characterizing real world safety profile of oral Janus kinase inhibitors among adult atopic dermatitis patients: evidence transporting from the rheumatoid arthritis population

Montez‐Rath, Maria E.; Lubwama, Robert; Kapphahn, Kris; Ling, Albee Y.; LoCasale, Robert; Robinson, Lacey B.; Chandross, Karen J.; Desai, Manisha

doi:10.1080/03007995.2022.2088715

Cited by 5 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The risk for MACE in patients with rheumatoid arthritis is higher than in the general population [ 32 ]. Compared with patients with AD, patients with rheumatoid arthritis tend to be older and have higher body mass index [ 33 ]. Therefore, a higher incidence of MACE in patients with rheumatoid arthritis treated with JAK inhibitors could be related in part to the specific patient profile [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure

Simpson,

Silverberg,

Nosbaum

et al. 2024

Am J Clin Dermatol

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure

Simpson,

Silverberg,

Nosbaum

et al. 2024

Am J Clin Dermatol

View full text Add to dashboard Cite

“…For example, one can think of the generalizability and transportability methods described above as a means to standardize the trial sample to resemble the target population. 6 In this manner, methods used to translate findings can also be combined with other types of studies (e.g., a comparative effectiveness cohort study, [78][79][80] estimating incidence of events [81][82][83] ) as a tool of standardization.…”

Section: Discussionmentioning

confidence: 99%

An Overview of Current Methods for Real-world Applications to Generalize or Transport Clinical Trial Findings to Target Populations of Interest

et al. 2023

Self Cite

View full text Add to dashboard Cite

It has been well established that randomized clinical trials have poor external validity, resulting in findings that may not apply to relevant-or target-populations. When the trial is sampled from the target population, generalizability methods have been proposed to address the applicability of trial findings to target populations. When the trial sample and target populations are distinct, transportability methods may be applied for this purpose. However, generalizability and transportability studies present challenges, particularly around the strength of their conclusions. We review and summarize state-ofthe-art methods for translating trial findings to target populations. We additionally provide a novel step-by-step guide to address these challenges, illustrating principles through a published case study. When conducted with rigor, generalizability and transportability studies can play an integral role in regulatory decisions by providing key real-world evidence.

show abstract

“…A large amount of data has been gathered from the use of small molecule inhibitors in rheumatology; however, rheumatoid arthritis and AD are diseases with two distinct age groups [70]. Most adverse events of JAKis are mild to moderate in severity [71][72][73].…”

Section: Jak Stat Pathwaymentioning

confidence: 99%

How to Understand Personalized Medicine in Atopic Dermatitis Nowadays?

Mesjasz

Kołkowski

Wollenberg

et al. 2023

IJMS

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a heterogeneous disease in terms of its phenotypical, barrier, and immunological presentation. Emerging therapies are undoubtedly contributing to a new chapter in the treatment of AD, bringing an excellent possibility of individualization, and thereby creating a tailored approach. The two most promising substance groups are biological drugs (dupilumab, tralokinumab, lebrikizumab, nemolizumab) and Janus kinase inhibitors (JAKis) (baricitinib, upadacitinib, and abrocitinib). The vision that certain well-defined phenotypes and endotypes, as well as personal preferences, may guide the future treatment of AD is both tempting and appealing, but not yet reality. The accessibility of new drugs such as biologics and small molecules has opened up the discussion regarding personalized medicine, referring to the complex nature of AD as well as the experiences from clinical trials and real-world evidence. We have now reached the point of creating new strategies and AD treatment goals by increasing the amount of new information concerning the efficacy and safety of new drugs. This article has reviewed the novel treatment options for AD in the light of the heterogeneity of this disease and proposes a broader vision on the strategy of personalized treatment of AD.

show abstract

Characterizing real world safety profile of oral Janus kinase inhibitors among adult atopic dermatitis patients: evidence transporting from the rheumatoid arthritis population

Cited by 5 publications

References 33 publications

Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure

Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure

An Overview of Current Methods for Real-world Applications to Generalize or Transport Clinical Trial Findings to Target Populations of Interest

How to Understand Personalized Medicine in Atopic Dermatitis Nowadays?

Contact Info

Product

Resources

About